Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23975138 | 0.94 | NAAA (0.62) | NAAASMN1; SMN2EPHX2NPC1PKM | |
| SCHEMBL23975364 | 0.94 | NAAA (0.62) | NAAASMN1; SMN2EPHX2NPC1PKM | |
| SCHEMBL22652025 | 0.81 | NAAA (0.63) | NAAASMN1; SMN2EPHX2NPC1PKM | |
| SCHEMBL17172545 | 0.80 | NAAA (0.82) | NAAASMN1; SMN2EPHX2NPC1PKM | |
| SCHEMBL27699972 | 0.79 | NAAA (0.55) | NAAASMN1; SMN2EPHX2NPC1PKM | |
| SCHEMBL28417481 | 0.78 | NAAA (0.42) | NAAASMN1; SMN2EPHX2NPC1EPHX1 | |
| SCHEMBL3184451 | 0.78 | NAAA (0.66) | NAAASMN1; SMN2EPHX2NPC1PKM | |
| SCHEMBL18412281 | 0.78 | NAAA (0.54) | NAAASMN1; SMN2EPHX2NPC1PKM | |
| SCHEMBL20794256 | 0.77 | NAAA (0.66) | NAAASMN1; SMN2EPHX2NPC1PKM | |
| SCHEMBL15426780 | 0.77 | NAAA (0.66) | NAAASMN1; SMN2EPHX2NPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | HAVCR2, CUL4A, PSMC3 | NAAA 914/4885SMN1; SMN2 3617/4885EPHX2 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.